参芪扶正注射液联合化疗对乳腺癌患者血清炎性因子及T细胞亚群的影响  

Effects of Shenqi Fuzheng Injection combined with chemotherapy on serum inflammatory factors and T lymphoid subsets in patients with breast cancer

作　　者：付倩 张颂 霍彦平[1] Fu Qian;Zhang Song;Huo Yanping(Department of Breast Surgery,Zhengzhou Central Hospital,Zhengzhou,Henan 450008,China)

机构地区：[1]郑州市中心医院乳腺外科,河南郑州450008

出　　处：《中国药物与临床》2025年第2期69-72,共4页Chinese Remedies & Clinics

基　　金：河南省医学科技攻关计划项目(2018020793)。

摘　　要：目的分析参芪扶正注射液联合化疗对乳腺癌患者血清炎性因子和T细胞的影响。方法选取2023年2月至2024年6月河南省郑州市中心医院收治60例乳腺癌患者,按随机数字表法将60例患者分为对照组与观察组,各30例。对照组行化疗,观察组化疗加参芪扶正注射液治疗。对比2组临床疗效、炎性因子水平、肿瘤标志物、T细胞亚群、不良反应。结果观察组治疗总有效率为83.3%(25/30),高于对照组的60.0%(18/30),χ^(2)=4.022,P=0.045;不良反应发生率为10.0%(3/30),低于对照组的33.3%(10/30),χ^(2)=4.813,P=0.028;且治疗后的白细胞介素-6为(9.7±1.4)pg/ml、白细胞介素-8为(23.4±2.0)μg/L,鳞状上皮细胞癌抗原为(1.38±0.22)μg/L、细胞角质蛋白19片段为(8.5±1.4)ng/ml、糖类抗原125为(41±5)U/ml,CD8^(+)为(21.6±1.8)%,分别低于对照组的(13.2±1.7)pg/ml、(30.2±2.5)μg/L、(2.23±0.32)μg/L、(12.4±2.0)ng/ml、(49±6)U/ml、(31.6±3.6)%;CD3^(+)为(65.3±7.3)%、CD4^(+)为(41.4±4.4)%、CD4^(+)/CD8^(+)为(1.91±0.35),高于对照组的(50.2±5.3)%、(29.9±2.8)%、(0.95±0.17),2组差异有统计学意义(P<0.05)。结论参芪扶正注射液联合化疗可减轻乳腺癌患者体内炎症反应,降低肿瘤标志物水平,改善T细胞亚群,且不良反应较少,值得临床借鉴。Objective To analyze the effects of Shenqi Fuzheng Injection combined with chemotherapy on serum inflammatory factors and T lymphocytes in patients with breast cancer.Methods A total of 60 patients with breast cancer admitted to Zhengzhou Central Hospital from February 2023 to June 2024 were prospectively selected and divided into a control group and an observation group according to the random number table,with 30 cases in each group.The control group received chemotherapy,and the observation group received chemotherapy combined with Shenqi Fuzheng Injection.The clinical efficacy,inflammatory factor levels,tumor markers,T lymphocyte subsets,and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 83.3%(25/30),significantly higher than that of the control group at 60.0%(18/30),χ^(2)=4.022,P=0.045.The incidence of adverse reactions in the observation group was 10.0%(3/30),significantly lower than that of the control group at 33.3%(10/30),χ^(2)=4.813,P<0.05.After treatment,the levels of interleukin-6,interleukin-8,squamous cell carcinoma antigen,cytokeratin 19 fragment,carbohydrate antigen 125,and CD8^(+)in the observation group were(9.7±1.4)pg/ml,(23.4±2.0)μg/L,(1.38±0.22)μg/L,(8.5±1.4)ng/ml,(41±5)U/ml,and(21.6±1.8)%,respectively,which were significantly lower than those in the control group at(13.2±1.7)pg/ml,(30.2±2.5)μg/L,(2.23±0.32)μg/L,(12.4±2.0)ng/ml,(49±6)U/ml,and(31.6±3.6)%,respectively,with P<0.05.After treatment,the levels of CD3^(+),CD4^(+),and the CD4^(+)/CD8^(+)ratio in the observation group were(65.3±7.3)%,(41.4±4.4)%,and(1.91±0.35)%,respectively,which were significantly higher than those in the control group at(50.2±5.3)%,(29.9±2.8)%,and(0.95±0.17),respectively(P<0.05).Conclusion Shenqi Fuzheng Injection combined with chemotherapy can reduce inflammation in breast cancer patients,reduce the level of tumor markers,improve T lymphoid subsets,and less adverse reactions,which is worthy of clinical reference.

关 键 词：乳腺肿瘤 参芪扶正注射液 化疗反应 药物相关性副作用和不良反应 

分 类 号：R73[医药卫生—肿瘤]